Orthofix Medical Inc. (NASDAQ:OFIX) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Orthofix Medical Inc. (NASDAQ:OFIX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $23.33.

OFIX has been the subject of a number of recent analyst reports. Roth Mkm restated a "buy" rating and issued a $22.00 target price (up from $20.00) on shares of Orthofix Medical in a report on Friday, November 8th. StockNews.com raised Orthofix Medical from a "hold" rating to a "buy" rating in a research report on Friday, January 31st. Canaccord Genuity Group assumed coverage on Orthofix Medical in a research report on Wednesday, January 22nd. They set a "buy" rating and a $24.00 price target for the company. Finally, Stifel Nicolaus upgraded Orthofix Medical from a "hold" rating to a "buy" rating and raised their price objective for the stock from $18.00 to $24.00 in a report on Friday, November 8th.

Insider Buying and Selling at Orthofix Medical

In other news, CFO Julie Andrews sold 4,655 shares of the stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $17.89, for a total transaction of $83,277.95. Following the completion of the transaction, the chief financial officer now directly owns 28,312 shares in the company, valued at approximately $506,501.68. This represents a 14.12 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Massimo Calafiore sold 10,078 shares of the company's stock in a transaction on Friday, January 10th. The shares were sold at an average price of $16.83, for a total transaction of $169,612.74. Following the completion of the sale, the chief executive officer now directly owns 133,354 shares in the company, valued at $2,244,347.82. This represents a 7.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 25,442 shares of company stock valued at $436,883 over the last three months. 2.60% of the stock is owned by company insiders.

Institutional Trading of Orthofix Medical

Several hedge funds and other institutional investors have recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Orthofix Medical by 14.0% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 71,371 shares of the medical device company's stock valued at $1,246,000 after acquiring an additional 8,772 shares during the last quarter. Soleus Capital Management L.P. boosted its holdings in Orthofix Medical by 13.1% in the fourth quarter. Soleus Capital Management L.P. now owns 686,374 shares of the medical device company's stock worth $11,984,000 after purchasing an additional 79,441 shares during the period. State of Wyoming increased its stake in Orthofix Medical by 206.8% during the fourth quarter. State of Wyoming now owns 9,432 shares of the medical device company's stock valued at $165,000 after purchasing an additional 6,358 shares during the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Orthofix Medical by 14.8% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 97,461 shares of the medical device company's stock worth $1,702,000 after purchasing an additional 12,578 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Orthofix Medical by 4.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,348 shares of the medical device company's stock worth $338,000 after buying an additional 836 shares during the last quarter. 89.76% of the stock is owned by institutional investors.

Orthofix Medical Price Performance

NASDAQ:OFIX traded down $0.10 during trading hours on Friday, hitting $18.49. The company's stock had a trading volume of 76,066 shares, compared to its average volume of 165,649. The company has a market capitalization of $706.50 million, a PE ratio of -5.91 and a beta of 1.10. Orthofix Medical has a 52-week low of $12.08 and a 52-week high of $20.73. The business's 50-day moving average is $17.94 and its two-hundred day moving average is $17.29. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.11 and a current ratio of 2.39.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.